| Mutational spectrum, copy number changes, and outcome: results of a sequencing study of patients with newly diagnosed myeloma BA Walker, EM Boyle, CP Wardell, A Murison, DB Begum, NM Dahir, ... Journal of clinical oncology 33 (33), 3911-3920, 2015 | 617 | 2015 |
| International Myeloma Working Group recommendations for the diagnosis and management of myeloma-related renal impairment MA Dimopoulos, P Sonneveld, N Leung, G Merlini, H Ludwig, E Kastritis, ... Journal of Clinical Oncology 34 (13), 1544-1557, 2016 | 435 | 2016 |
| Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms BA Walker, CP Wardell, L Melchor, A Brioli, DC Johnson, MF Kaiser, ... Leukemia 28 (2), 384-390, 2014 | 342 | 2014 |
| APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma BA Walker, CP Wardell, A Murison, EM Boyle, DB Begum, NM Dahir, ... Nature communications 6 (1), 6997, 2015 | 332 | 2015 |
| Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial GH Jackson, FE Davies, C Pawlyn, DA Cairns, A Striha, C Collett, ... The Lancet Oncology 20 (1), 57-73, 2019 | 324 | 2019 |
| Single-cell genetic analysis reveals the composition of initiating clones and phylogenetic patterns of branching and parallel evolution in myeloma L Melchor, A Brioli, CP Wardell, A Murison, NE Potter, MF Kaiser, ... Leukemia 28 (8), 1705-1715, 2014 | 287 | 2014 |
| Guidelines for acquisition, interpretation, and reporting of whole-body MRI in myeloma: myeloma response assessment and diagnosis system (MY-RADS) C Messiou, J Hillengass, S Delorme, FE Lecouvet, LA Moulopoulos, ... Radiology 291 (1), 5-13, 2019 | 242 | 2019 |
| Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial MA Dimopoulos, F Gay, F Schjesvold, M Beksac, R Hajek, KC Weisel, ... The Lancet 393 (10168), 253-264, 2019 | 242 | 2019 |
| Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients V Shah, AL Sherborne, BA Walker, DC Johnson, EM Boyle, S Ellis, ... Leukemia 32 (1), 102-110, 2018 | 233 | 2018 |
| Bortezomib inhibits human osteoclastogenesis I Von Metzler, H Krebbel, M Hecht, RA Manz, C Fleissner, M Mieth, ... Leukemia 21 (9), 2025-2034, 2007 | 220 | 2007 |
| Angiogenesis in multiple myeloma C Jakob, J Sterz, I Zavrski, U Heider, L Kleeberg, C Fleissner, M Kaiser, ... European journal of cancer 42 (11), 1581-1590, 2006 | 215 | 2006 |
| Translocations at 8q24 juxtapose MYC with genes that harbor superenhancers resulting in overexpression and poor prognosis in myeloma patients BA Walker, CP Wardell, A Brioli, E Boyle, MF Kaiser, DB Begum, NB Dahir, ... Blood cancer journal 4 (3), e191-e191, 2014 | 209 | 2014 |
| Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 … MV Mateos, H Nahi, W Legiec, S Grosicki, V Vorobyev, I Spicka, ... The lancet haematology 7 (5), e370-e380, 2020 | 206 | 2020 |
| Characterization of IGH locus breakpoints in multiple myeloma indicates a subset of translocations appear to occur in pregerminal center B cells BA Walker, CP Wardell, DC Johnson, MF Kaiser, DB Begum, NB Dahir, ... Blood, The Journal of the American Society of Hematology 121 (17), 3413-3419, 2013 | 203 | 2013 |
| Global methylation analysis identifies prognostically important epigenetically inactivated tumor suppressor genes in multiple myeloma MF Kaiser, DC Johnson, P Wu, BA Walker, A Brioli, F Mirabella, ... Blood, The Journal of the American Society of Hematology 122 (2), 219-226, 2013 | 193 | 2013 |
| Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group P Moreau, SK Kumar, J San Miguel, F Davies, E Zamagni, N Bahlis, ... The Lancet Oncology 22 (3), e105-e118, 2021 | 192 | 2021 |
| Serum concentrations of DKK‐1 correlate with the extent of bone disease in patients with multiple myeloma M Kaiser, M Mieth, P Liebisch, R Oberländer, J Rademacher, C Jakob, ... European journal of haematology 80 (6), 490-494, 2008 | 192 | 2008 |
| Genome-wide association study identifies multiple susceptibility loci for multiple myeloma JS Mitchell, N Li, N Weinhold, A Försti, M Ali, M Van Duin, G Thorleifsson, ... Nature communications 7 (1), 12050, 2016 | 183 | 2016 |
| Bortezomib increases osteoblast activity in myeloma patients irrespective of response to treatment U Heider, M Kaiser, C Müller, C Jakob, I Zavrski, CO Schulz, C Fleissner, ... European journal of haematology 77 (3), 233-238, 2006 | 178 | 2006 |
| Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma MA Dimopoulos, A Palumbo, P Corradini, M Cavo, M Delforge, ... Blood, The Journal of the American Society of Hematology 128 (4), 497-503, 2016 | 170 | 2016 |
Gareth MorganNYUVerified email at nyulangone.org
